brand logo

Am Fam Physician. 2021;104(6):626-635

Related Letter to the Editor: Simplification in Hepatitis C Treatment

Patient information: A handout on this topic is available at

Author disclosure: No relevant financial affiliations.

Screening recommendations and treatment guidelines for hepatitis C virus (HCV) infection have been updated. People at the greatest risk of HCV infection are those between 18 and 39 years of age and those who use injection drugs. Universal screening with an anti-HCV antibody test with follow-up reflex HCV RNA polymerase chain reaction testing for positive results to confirm active disease is recommended at least once for all adults 18 years and older and during each pregnancy. Any person with ongoing risk factors should be screened periodically as long as the at-risk behavior persists. One-time screening is recommended for patients younger than 18 years with risk factors. For treatment-naive adults without cirrhosis or with compensated cirrhosis, a simplified treatment regimen consisting of eight weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvir results in greater than 95% cure rates. Undetectable HCV RNA 12 weeks after completing therapy is considered a virologic cure (i.e., sustained virologic response). A sustained virologic response is associated with lower all-cause mortality and improves hepatic and extrahepatic manifestations, cognitive function, physical health, work productivity, and quality of life. In patients with compensated cirrhosis, posttreatment surveillance for hepatocellular carcinoma and esophageal varices should include abdominal ultrasonography (with or without alpha fetoprotein) every six months and upper endoscopy every two to three years. In the absence of cirrhosis, no liver-related follow-up is recommended.

Hepatitis C virus (HCV) infection, an underdiagnosed and undertreated multifaceted systemic disease, has a protracted chronic phase with hepatic and extrahepatic manifestations that affects an estimated 3.7 million people in the United States.15 From 2010 to 2018, the incidence of acute HCV infection among people 18 to 39 years of age quadrupled because of the opioid epidemic and the associated increase in people who inject drugs.18 Globally, less than 5% of people with HCV have been diagnosed, and less than 1% have received treatment.1,6,7

Clinical recommendation Evidence rating Comments
Screen for HCV infection in adults 18 to 79 years of age, during each pregnancy, and for patients with at-risk behavior for as long as the behavior persists.17,20,21 B Centers for Disease Control and Prevention, U.S. Preventive Services Task Force, and American College of Obstetricians and Gynecologists
Anti-HCV antibody testing with follow-up reflex HCV RNA polymerase chain reaction testing is recommended for initial testing.8,15,17,24 C Accurate tests for detecting HCV
Hepatitis A and hepatitis B vaccinations should be administered to people with HCV. A pneumococcal polysaccharide vaccine is indicated for adults 19 to 64 years of age with chronic hepatic disease and cirrhosis.8,15,17,18 C Expert opinion and consensus guideline from the Advisory Committee on Immunization Practices and Centers for Disease Control and Prevention
Adults with HCV infection who meet criteria for treatment with a simplified regimen should be treated with eight weeks of glecaprevir/pibrentasvir (Mavyret) or 12 weeks of sofosbuvir/velpatasvir (Epclusa), regardless of the HCV genotype.8,15,18,40,54 B Placebo-controlled trials show a > 95%sustained viral response at 12 weeks posttreatment; sustained virologic response is associated with improved patient-oriented outcomes in long-term cohort studies
All people should receive education about preventing HCV transmission and reducing the progression of hepatic disease.8,15,17 C Expert opinion and consensus guideline
RecommendationSponsoring organization
Do not repeat hepatitis C virus antibody testing in patients with a previous positive hepatitis C virus test result. Instead, order hepatitis C viral load testing for assessment of active vs. resolved infection.American Society for Clinical Pathology
Do not repeat hepatitis C viral load testing outside of antiviral therapy.American Association for the Study of Liver Diseases

The World Health Organization and the National Academies of Sciences, Engineering, and Medicine have developed strategies to eliminate HCV by 2030.1,6,7 Strategies include expanded screening, better access to appropriate care, and highly effective direct-acting antiviral medication.1,6,7 The United States is not on track to meet this goal.1,4,6,7 Estimates for 2018 indicated that 52% of people in the United States were aware of their disease, and 37% had received treatment.4 Current barriers to access and treatment include the asymptomatic nature of chronic HCV, lack of access to specialty care, high cost of treatment, insurance guidelines requiring advanced stages of liver fibrosis before approving therapy, substance use and sobriety requirements, and prescriber restrictions (,615


Injection drug use accounts for approximately 60% of acute HCV infections in the United States.1,2,8,15 Men who have sex with men (particularly people with HIV or those who have unprotected anal intercourse), perinatal transmission, and exposure to blood products before 1992 are other sources.2,8,15,16 Nosocomial exposure (e.g., hemodialysis, needlestick) and cosmetic exposure (e.g., tattooing, piercing) are less likely routes of transmission if standard infection-control practices are followed8,15 (Table 12,8,1518).

Community exposure
 Infants born to a person with hepatitis C virus infection
 Injection drug use
 Men who have sex with men (particularly people with HIV or those who have unprotected anal intercourse)
 Percutaneous or parenteral exposure in an unregulated setting with poor infection control practices
Hospital exposure
 Long-term hemodialysis
 Needlestick injuries
 Receipt of clotting factor concentrate in the United States before 1987
 Transfusion of blood products before 1992
 HIV or hepatitis B infection
 Sexually active person starting pre-exposure prophylaxis for HIV
 Unexplained chronic hepatic disease including abnormal liver enzymes (mild, intermittent or markedly elevated)


The Centers for Disease Control and Prevention recommends universal HCV screening at least once for all adults 18 years and older and during each pregnancy 19 (Table 2).17 The American College of Obstetricians and Gynecologists recommends screening all pregnant individuals during each pregnancy.20 People at risk, or those who request testing, should be screened periodically for as long as the at-risk behavior persists.17 One-time screening is recommended for patients younger than 18 years with risk factors.17 The U.S. Preventive Services Task Force recommends screening all asymptomatic adults (including people who are pregnant) 18 to 79 years of age and people younger or older who are at high risk of infection.21 Anti-HCV antibody testing (third-generation enzyme-linked immunosorbent assay with 99% sensitivity and specificity) is the screening test of choice with follow-up reflex HCV RNA polymerase chain reaction testing for positive results to confirm the active disease.8,15,17 Point-of-care testing allows for expanded screening.8,22 The OraQuick HCV rapid antibody test is a Clinical Laboratory Improvement Amendments–waived point-of-care test with reliable results (sensitivity, 94.1%; specificity, 99.5%; positive predictive value, 72.7%; and negative predictive value, 99.9%).8,22

Universal HCV screening:
 HCV screening at least once in a lifetime for all adults ≥ 18 years, except in settings where the prevalence of HCV infection (HCV RNA-positivity) is < 0.1%*
 HCV screening for all pregnant people during each pregnancy, except in settings where the prevalence of HCV infection (HCV RNA-positivity) is < 0.1%*
One-time HCV testing regardless of age or setting prevalence among people with recognized risk factors or exposures:
 People with HIV
 People who ever injected drugs and shared needles, syringes, or other drug preparation equipment, including those who injected once or a few times many years ago
 People with select medical conditions, including people who ever received maintenance hemodialysis, and people with persistently abnormal alanine transaminase levels
 Recipients of transfusions or organ transplants, including people who received clotting factor concentrates produced before 1987, people who received a transfusion of blood or blood components before July 1992, people who received an organ transplant before July 1992, and people who were notified that they received blood from a donor who later tested positive for HCV infection
 Health care, emergency medical, and public safety personnel after needlesticks, sharps, or mucosal exposures to HCV-positive blood
 Children born to mothers with HCV infection
Routine periodic testing for people with ongoing risk factors, while risk factors persist:
 People who currently inject drugs and share needles, syringes, or other drug preparation equipment
 People with select medical conditions, including people who ever received maintenance hemodialysis
Any person who requests HCV testing should receive it, regardless of disclosure of risk, because many people might be reluctant to disclose stigmatizing risks

Acute HCV Infection

Most patients with acute HCV infection are asymptomatic. Anorexia, malaise, jaundice, and abdominal pain occur in 10% to 20% of patients two to 12 weeks after exposure.11,15,17,23 The HCV antibody becomes detectable four to 10 weeks after exposure and is present in 97% of patients by six months.17,23 A positive HCV antibody test reflects active disease, a resolved infection, or a rare false-positive result.24 The presence of HCV RNA indicates acute infection and can be present as early as one to two weeks after exposure.23,25 Alanine transaminase levels peak at 10 to 20 times the upper limit of normal, typically rising eight to 10 weeks after infection.23 Once infected, 15% to 45% of patients spontaneously clear the virus8,15,23,25 (Figure 18,15,22,23,2630). Factors associated with an increased rate of clearance include younger age, jaundice, elevated alanine transaminase level, hepatitis B surface antigen (HBsAg) positivity, female sex, HCV genotype 1, and host genetic polymorphisms (i.e., IL28B gene).15,17,23,31,32 Clearance rates are lower in patients with HIV infection.17,23

Chronic HCV Infection

The persistence of HCV RNA after six months indicates chronic HCV infection. Although chronic HCV is insidious with few symptoms or physical signs, two quality-of-life studies highlight symptom clusters (i.e., neuropsychiatric, gastrointestinal, algesic, and dysesthetic) in treatment-naive patients with chronic HCV33,34 (eTable A).

General body pain
Joint pain
Muscle pain
Light sensitivity
Noise sensitivity
Skin problems
Abdominal pain
Day sweats
Food intolerance
Night sweats
Poor appetite
Mental tiredness
Physical tiredness
Poor concentration
Sleep problems

Hepatic sequelae include chronic hepatitis, fibrosis, cirrhosis, hepatocellular decompensation, and hepatocellular carcinoma (HCC).8,15,23 Fulminant hepatitis usually does not occur.15 Approximately 20% to 30% of patients with chronic HCV develop cirrhosis over 25 to 30 years.23 Risk factors for cirrhosis include male sex, being older than 50 years, hepatitis B virus infection, HIV infection, immunosuppressive therapy, alcohol use, obesity, hepatotoxic drugs, and nonalcoholic steatohepatitis.15,23,26 Elevated bilirubin level, hypoalbuminemia, prolonged prothrombin time, or decreased platelet count suggests cirrhosis.3537 Patients with cirrhosis are at greater risk of developing HCC (1% to 4% per year) and hepatocellular decompensation (2% to 5% per year) manifested by ascites, encephalopathy, jaundice, spontaneous bacterial peritonitis, or variceal hemorrhage.23,27,28,3840

Up to 74% of patients develop an extrahepatic manifestation, several of which can negatively impact quality of life8,15,2730,40,41 (eFigure A). The fourfold increase of diabetes mellitus contributes to accelerated liver fibrosis and an increased incidence of cardiovascular disease.29,30 Direct-acting antiviral therapy is helpful for many extrahepatic conditions.8,15,2730,42

Pretreatment Assessment

The pretreatment assessment begins with a complete medical history that includes identifying alcohol and drug use, potential drug-drug interactions, hepatotoxic agents, comorbid conditions, risk factors, prior treatment, and the need for vaccinations8,15,17,4245 (Figure 28,15,4245). Noninvasive testing such as transient elastography with an indirect marker of fibrosis (e.g., Aspartate transaminase to Platelet Ratio Index [APRI], Fibrosis-4 [FIB-4], Fibrosure) can be used to determine the extent of liver fibrosis or cirrhosis8,15,37,40 (Table 38,15,18). Laboratory testing includes a quantitative HCV RNA, HIV, liver panel (aspartate transaminase, alanine transaminase, bilirubin, albumin), complete blood count, estimated glomerular filtration rate (eGFR) measurement, and pregnancy testing.8,15,16,42 Because all direct-acting antiviral medications carry a U.S. Food and Drug Administration (FDA) boxed warning for the risk of hepatitis B reactivation in coinfected patients, testing is recommended for current (HBsAg positive) and past (hepatitis B surface antibody [anti-HBs] and hepatitis B core antibody [anti-HBc]) hepatitis B virus infection before therapy.8,15 Vaccination against hepatitis A, hepatitis B, and pneumococcal disease (pneumococcal polysaccharide vaccine for adults 19 to 64 years of age) should be administered to people with chronic liver disease, cirrhosis, or HCV.8,15,17

Serum markersComponentsMetricsInterpretation
Aspartate transaminase to Platelet Ratio Index scoreAspartate transaminase level, platelet count≥ 0.7 U per L (0.01 μkat per L) has sensitivity of 77% and specificity of 72% for detecting F2 fibrosis or greater
Cutoff of at least 1 has sensitivity of 61% to 76% and specificity of 64% to 72% for F3, F4 fibrosis/cirrhosis
Cutoff of at least 2 has a sensitivity of 46% and specificity of 91% for cirrhosis
Predicts severe fibrosis and cirrhosis or low risk of fibrosis or cirrhosis but does not differentiate intermediate stages from severe fibrosis
Fibrosure (combination of Fibrotest and Actitest)Age, sex, alpha-2-macroglobulin, haptoglobin, apolipoprotein A1C, gamma-glutamyl transferase, total bilirubinMild, significant, or intermediateFibrotest estimates hepaticfibrosisActitest indicates hepatic inflammation (high specificity for significant fibrosis)
Fibrosis-4Alanine transaminase level, aspartate transaminase level, platelet count, ageScore < 1.45 has 74% sensitivity and a negative predictive value of 95% for excluding advanced fibrosis (F3 or F4)
Score > 3.25 has a positive predictive value of 82% and specificity of 98% in confirming cirrhosis
Score = 1.45 to 3.25 requires another test to confirm fibrosis
Good at confirming or excluding cirrhosis if score > 3.25
Direct serum markersProcollagen type (I, III, IV), matrix metalloproteinases, cytokines, chemokinesVariable effectiveness in predicting liver fibrosisTo be determined
Radiologic assessment
Fibroscan (transient elastography)Transducer probe mounted on axis of a vibrator> 12.5 kPa has high sensitivity (87%) and specificity (91%) for cirrhosisDetection of advanced fibrosis (F3, F4) and cirrhosis

Treatment and Outcome Overview

Direct-acting antiviral therapy is more effective, better tolerated, and the treatment course is shorter than older interferon and ribavirin-based regimens. The need for pretreatment genotyping and on-treatment monitoring is decreased with these agents.15,40,46,47 As a prevention strategy, the test-and-treat option calls for treatment at the time of diagnosis, instead of waiting for spontaneous resolution of the acute infection in all patients except those with a life expectancy of less than one year.8,15,47 Undetectable HCV RNA 12 weeks after completion of treatment indicates a sustained virologic response and is indicative of a virologic cure as reflected by the high concordance at the five-year mark.8,15,27,4749 A sustained virologic response is associated with lower all-cause mortality and improves hepatic and extrahepatic manifestations, cognitive function, physical health, work productivity, and quality of life.8,15,40,41,47,4952


FDA-approved pangenotypic direct-acting antiviral treatments include glecaprevir/pibrentasvir (Mavyret), sofosbuvir/velpatasvir (Epclusa), and sofosbuvir/velpatasvir/voxilaprevir (Vosevi).8,15,18,40,42,47,53 Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are the direct-acting antiviral medications that comprise the simplified treatment regimens recommended by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America and are the focus of this article8,15,18,47,5456 (Table 48,15,18,40,42,53,56).

RegimenMechanism of actionGenotypeDosageCost*
Glecaprevir/pibrentasvir (Mavyret; 100 mg/40 mg [total per day = 300 mg/120 mg])NS3/4A, NS5A1 through 63 tablets per day for 8 weeksNot available ($25,000)
Sofosbuvir/velpatasvir (Epclusa; 400 mg/100 mg)NS5A, NS5B1 through 6 no evidence of cirrhosis;
1, 2, 4, 5, 6 for compensated cirrhosis
1 tablet per day for 12 weeks$11,000 ($70,000)

Glecaprevir/pibrentasvir is indicated for patients without cirrhosis and for those with compensated cirrhosis (Child-Pugh classification A; Table 5).8,15,18 Glecaprevir/pibrentasvir is not recommended in Child-Pugh classification B cirrhosis and is contraindicated in Child-Pugh classification C cirrhosis.8,15,18 There is no restriction based on renal function.8,15,18 Sofosbuvir/velpatasvir is used for patients without cirrhosis and patients with compensated cirrhosis, including Child-Pugh classification B cirrhosis and Child-Pugh classification C cirrhosis (with ribavirin).8,15,18 Based on recent studies, sofosbuvir/velpatasvir is now approved for use in patients with an eGFR of 30 mL per minute per m2 or less and patients on hemodialysis.8,15,57 The most common adverse effects include fatigue, headache, insomnia, and nausea.8,15,18,42,47 Only 1% to 2% of patients discontinue treatment because of adverse events.8,15,18

Albumin> 3.5 g per dL (35 g per L)2.8 to 3.5 g per dL (28 to 35 g per L)< 2.8 g per dL
AscitesNoneMild to moderateSevere
Bilirubin< 2 mg per L (34.21 μmol per L)2 to 3 mg per L (34.21 to 51.31 μmol per L)> 3 mg per L
EncephalopathyNoneMild to moderateSevere
International normalized ratio< 1.71.7 to 2.3> 2.3


Herbal and dietary supplements should be discontinued.18,42 Acetaminophen is generally safe if less than 2 g per day is used.8,15 The blood glucose level and international normalized ratio (INR) should be closely monitored to prevent hypoglycemia and subtherapeutic INR levels.8,15,44,45 The opioid use disorder treatments methadone, buprenorphine, and buprenorphine/naloxone (Suboxone) do not have significant interactions with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir 8,15,18,42,43,4547,53 (eTable B).

DrugGlecaprevir/pibrentasvir (Mavyret)Sofosbuvir/velpatasvir (Epclusa)
AmiodaroneSafe to useUnsafe to use (life-threatening bradycardia)
Carbamazepine (Tegretol)Unsafe to useUnsafe to use
Diabetes mellitus medicationsMonitor to prevent hypoglycemiaMonitor to prevent hypoglycemia
Ethinyl estradiol–containing contraceptivesUnsafe to useSafe to use
Herbal medicineUnsafe to useUnsafe to use
Methadone, buprenorphine, buprenorphine/naloxone (Suboxone)Safe to useSafe to use
Proton pump inhibitorsSafe to useUnsafe to use (if must use, should be taken with food 4 hours before 20-mg omeprazole [Prilosec])
StatinsUnsafe to use with atorvastatin (Lipitor), lovastatin (Mevaor), or simvastatin (Zocor; increased statin levels leading to myopathy and rhabdomyolysis)Safe to use atorvastatin and rosuvastatin (Crestor) at low doses (monitor for myopathy and rhabdomyolysis)
St. John's wortUnsafe to useUnsafe to use
Warfarin (Coumadin)Monitor for subtherapeutic international normalized ratio levelsMonitor for subtherapeutic international normalized ratio levels


In adults with HCV and without cirrhosis who meet criteria for treatment with the simplified regimen, studies have consistently exhibited a greater than 95% sustained viral response at 12 weeks posttreatment with eight weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvir, regardless of the HCV genotype.8,15,18,40,54

Patients with treatment-naive HCV with compensated cirrhosis (Child-Pugh classification A) who qualify for the simplified treatment regimen need a clinical evaluation to rule out ascites and hepatic encephalopathy. Abdominal ultrasonography within six months of starting treatment is required to exclude HCC and subclinical ascites.8,15,18 Any evidence of hepatic decompensation or HCC is a contraindication for the simplified treatment regimen and requires a referral.8,15 Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir have shown similar high curative rates to patients without cirrhosis.8,15,18,54,55 Glecaprevir/pibrentasvir is effective against all HCV genotypes.8,15,18 If sofosbuvir/velpatasvir is selected, pretreatment genotype testing to identify patients with genotype 3 is required to eliminate possible nonstructural protein 5A resistance-associated substitution at Y93H.8,15,54 If the resistance-associated substitution result is positive, patients should be treated with glecaprevir/pibrentasvir or referred to a specialist.8,15,18 Because hepatic decompensation occurs rarely during treatment of HCV infection, a complete blood count; measurement of alanine transaminase, aspartate transaminase, bilirubin, and albumin levels; INR; and eGFR should be obtained within three months of initiating treatment to detect early liver injury.8,15,18


Specialty consultants serving as mentors to primary care physicians through videoconferencing were used in Project ECHO to provide treatment for patients with HCV in rural communities across New Mexico.710,1214 In the ASCEND study, primary care physicians and nurse practitioners treated a cohort of patients at several urban federally qualified health centers.814 Both studies demonstrated that nonspecialists could provide safe, effective HCV treatment with outcomes equivalent to specialists.815

Family physicians can provide greater access to treatment, comparable treatment outcomes to specialists, and comprehensive posttreatment continuity of care.1,2,615 Family physicians with expertise in multiple treatment regimens and coinfections or comorbidities can continue to treat or comanage their patients8,11,13,15,48,58 (eFigure B).

Treatment Failure

Patients with clinical deterioration or laboratory changes during treatment should be promptly referred. Once a patient achieves sustained virologic response after 12 weeks of treatment, any detectable amount of HCV RNA indicates reinfection or relapse.8,48,5860 Patients who are reinfected (continued at-risk behavior with subsequent positive HCV RNA) can be treated with the simplified regimen.8 If relapse (usually within 12 weeks of sustained virologic response) is a consideration, the patient should be referred to a specialist for genotypic testing and treatment.8,48,5860 Patients with persistently elevated transaminase levels after sustained virologic response should be evaluated for other causes of hepatic disease.8,15,18,6163

Posttreatment Management

No liver-specific follow-up is recommended for patients without cirrhosis.8,15,17,18 For patients with cirrhosis, surveillance is recommended indefinitely for HCC and esophageal varices. Surveillance consists of abdominal ultrasonography (with or without alpha fetoprotein) every six months and upper endoscopy every two to three years, depending on the initial endoscopy results.8,15,18,49

Access to community resources and appropriate addiction, medical, psychiatric, and preventive services with long-term monitoring of patients for the early identification and management of hepatic and extrahepatic manifestations, reinfection, or other medical, psychiatric, and social issues is important.8,15,41,57 Patients should avoid alcohol, tobacco, and illicit drugs.8,15 Harm-reduction interventions, risk reduction, and liver-protective measures are necessary to prevent reinfection and additional liver damage8,15,17,18,42 (Table 61,8,1518,42,48,63). HCV RNA testing is indicated periodically for people with ongoing at-risk behavior and anytime an increase in transaminase levels occurs.8,15,18

Comorbid conditions
 Hepatic or extrahepatic manifestations, and any medical conditions that affect the liver
 Obesity, diabetes mellitus, nonalcoholic steatohepatitis (weight loss is essential)
Diet, drugs, and tobacco
 Avoid alcohol, quit smoking, and avoid cannabis use
 Avoid hepatotoxic drugs (complementary, herbal, supplemental, over-the-counter, prescribed)
 Balanced low-fat diet with target body mass index < 25 kg per m2
 Coffee (3 cups per day is thought to be liver protective)
 Less than 2,000 mg salt per day
Household transmission
 Rare form of transmission; family members should avoid blood-contaminated items (e.g., razors, toothbrushes, nail clippers)
Injection drug use
 Addiction treatment if necessary
 Avoid nonregulated tattoo parlors
 Counseling for drug and alcohol misuse (2% to 3% per year reinfection rate for injection drug use)*
 Do not donate blood, organs, or semen
 Harm-reduction measures (opioid agonist therapy and needle/syringe exchange)
 Inform patient of measures to decrease risk of transmission
Perinatal transmission
 Breastfeeding is safe when nipples are not damaged, cracked, or bleeding
 Maternal HCV antibody passively transfers and can be present for up to 18 months after delivery
 Mode of delivery does not matter for preventing transmission
 Transmission occurs in 5.8% of pregnancies
Periodic HCV RNA testing for people with continued at-risk behavior*
 Anxiety/depression/mental health issues/substance abuse
 Behavior issues/modification
Sexual exposure
 Heterosexual transmission is low; therefore, patients in long-term monogamous relationships do not need to alter their sex practices based on HCV infection alone
 Men who have sex with men who have HCV should be advised to use latex condoms and avoid rough sex
 People starting pre-exposure prophylaxis for HIV
 People with HIV/HCV coinfection should be encouraged to use barrier precautions (3% per year reinfection rate)*
 People with multiple sex partners should be encouraged to use barrier precautions

The article updates previous articles on this topic by Moyer, et al.,64 Ward, et al.,65 Wilkins, et al.,66 and Wilkins, et al.2

Data Sources: An online search was conducted using the key terms hepatitis C, acute HCV infection, chronic HCV infection, cirrhosis, hepatocellular carcinoma, hepatic decompensation, transmission, risk factors, elevated liver enzymes, anti-HCV antibody testing, HCV RNA, WHO guidelines, NASEM guidelines, hepatic and extrahepatic complications, HCV quality of life, DAA therapy, diagnosis and management of HCV, complications of HCV, coinfections and morbidity, AASLD-IDSA guidelines, screening guidelines for HCV, Centers for Disease Control and Prevention and U.S. Preventive Services Task Force guidelines, pretreatment assessment, follow-up after treatment, cost, when to refer HCV, family medicine's role, and hepatitis B and HIV. A broad-based search of the topic was performed in the Agency for Healthcare Research and Quality,, HCV guidelines, PubMed, and the U.S. Preventive Services Task Force. The search was later refined to identify major scholarly and professional resources using the following databases: Centers for Disease Control and Prevention, PubMed, the Cochrane database, and OVID. Search dates: October 1, 2020, and February 19 to May 28, 2021.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.